Symbols / ALNY Stock $301.19 -0.30% Alnylam Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
ALNY (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Yvonne L. Greenstreet M.B.A., M.D.
Exch · Country NMS · United States
Market Cap 40.19B
Enterprise Value 40.01B
Income 313.75M
Sales 3.71B
FCF (ttm) 128.79M
Book/sh 5.96
Cash/sh 21.93
Employees 2,500
Insider 10d —
IPO Jun 01, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 129.82
Forward P/E 21.35
PEG 0.60
P/S 10.82
P/B 50.52
P/C —
EV/EBITDA 71.79
EV/Sales 10.77
Quick Ratio 2.51
Current Ratio 2.76
Debt/Eq 376.19
LT Debt/Eq —
EPS (ttm) 2.32
EPS next Y 14.11
EPS Growth —
Revenue Growth 84.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-02-12
ROA 6.81%
ROE 73.28%
ROIC —
Gross Margin 81.64%
Oper. Margin 12.01%
Profit Margin 8.45%
Shs Outstand 133.43M
Shs Float 132.07M
Insider Own 0.19%
Instit Own 101.07%
Short Float 5.03%
Short Ratio 4.37
Short Interest 5.03M
52W High 495.55
vs 52W High -39.22%
52W Low 245.96
vs 52W Low 22.45%
Beta 0.38
Impl. Vol. 0.20%
Rel Volume 1.26
Avg Volume 1.25M
Volume 1.57M
Target (mean) $449.12
Tgt Median $448.00
Tgt Low $310.00
Tgt High $566.00
# Analysts 25
Recom Buy
Prev Close $302.11
Price $301.19
Change -0.30%
About

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$449.12
Mean price target
2. Current target
$301.19
Latest analyst target
3. DCF / Fair value
$17.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$301.19
Low
$310.00
High
$566.00
Mean
$449.12

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-13 main Truist Securities Buy → Buy $505
2026-03-25 main Chardan Capital Buy → Buy $425
2026-03-25 reit HC Wainwright & Co. Buy → Buy $510
2026-03-16 down Jefferies Buy → Hold $330
2026-02-18 reit HC Wainwright & Co. Buy → Buy $510
2026-02-17 up Freedom Broker Hold → Buy $410
2026-02-17 main Canaccord Genuity Buy → Buy $429
2026-02-13 main Chardan Capital Buy → Buy $425
2026-02-12 main Needham Buy → Buy $510
2026-01-30 main Morgan Stanley Equal-Weight → Equal-Weight $408
2026-01-30 main B of A Securities Buy → Buy $462
2026-01-30 main HC Wainwright & Co. Buy → Buy $510
2026-01-28 init Barclays — → Overweight $527
2026-01-20 main RBC Capital Outperform → Outperform $465
2026-01-20 main Wells Fargo Equal-Weight → Equal-Weight $376
2026-01-12 main B of A Securities Buy → Buy $529
2026-01-12 main Needham Buy → Buy $529
2026-01-08 main Truist Securities Buy → Buy $530
2025-12-15 main Leerink Partners Market Perform → Market Perform $351
2025-12-11 main Stifel Buy → Buy $508
News
RSS: Latest ALNY news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-06 MCLAUGHLIN MELISSA Officer — 3,910 $316.61 $1,274,343
2026-03-05 GARG PUSHKAL Officer — 4,713 $319.03 $1,524,796
2026-03-05 FITZGERALD KEVIN JOSEPH Officer — 1,291 $319.03 $417,685
2026-03-04 POULTON JEFFREY V Chief Financial Officer — 2,468 $319.03 $797,351
2026-03-04 TANGULER TOLGA Officer — 2,309 $319.03 $745,984
2026-03-04 GREENSTREET YVONNE L Chief Executive Officer — 2,933 $319.03 $947,581
2026-03-03 GARG PUSHKAL Officer — 3,492 $316.74 $1,130,131
2026-03-03 FITZGERALD KEVIN JOSEPH Officer — 3,250 $316.55 $1,051,773
2026-03-02 POULTON JEFFREY V Chief Financial Officer — 4,769 $0.00 $0
2026-03-02 POULTON JEFFREY V Chief Financial Officer — 2,206 $323.62 $722,801
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
3,713.94
+65.19%
2,248.24
+22.97%
1,828.29
+76.23%
1,037.42
Operating Revenue
3,713.94
+65.19%
2,248.24
+22.97%
1,828.29
+76.23%
1,037.42
Cost Of Revenue
681.87
+110.86%
323.37
+4.18%
310.41
+83.87%
168.82
Reconciled Cost Of Revenue
681.87
+110.86%
323.37
+4.18%
310.41
+83.87%
168.82
Gross Profit
3,032.07
+57.52%
1,924.87
+26.81%
1,517.89
+74.75%
868.60
Operating Expense
2,530.49
+20.40%
2,101.76
+16.76%
1,800.06
+8.85%
1,653.67
Research And Development
1,319.78
+17.19%
1,126.23
+12.13%
1,004.41
+13.75%
883.01
Selling General And Administration
1,210.71
+24.11%
975.53
+22.61%
795.65
+3.24%
770.66
General And Administrative Expense
1,210.71
+24.11%
975.53
+22.61%
795.65
+3.24%
770.66
Salaries And Wages
668.30
+25.84%
531.08
+25.46%
423.30
+2.80%
411.75
Other Gand A
348.98
+27.11%
274.54
+21.12%
226.66
-0.12%
226.94
Total Expenses
3,212.36
+32.46%
2,425.13
+14.91%
2,110.47
+15.80%
1,822.49
Operating Income
501.58
+383.56%
-176.88
+37.31%
-282.18
+64.06%
-785.07
Total Operating Income As Reported
501.58
+383.56%
-176.88
+37.31%
-282.18
+64.06%
-785.07
EBITDA
631.44
+453.06%
-178.85
+30.74%
-258.24
+72.13%
-926.56
Normalized EBITDA
676.22
+13477.17%
-5.05
+96.64%
-150.30
+79.18%
-722.00
Reconciled Depreciation
55.66
-1.79%
56.67
+4.84%
54.05
+21.56%
44.47
EBIT
575.78
+344.47%
-235.52
+24.59%
-312.30
+67.84%
-971.02
Total Unusual Items
-44.78
+74.23%
-173.79
-61.01%
-107.94
+47.23%
-204.56
Total Unusual Items Excluding Goodwill
-44.78
+74.23%
-173.79
-61.01%
-107.94
+47.23%
-204.56
Special Income Charges
-42.47
0.00
0.00
+100.00%
-76.59
Other Special Charges
42.47
—
—
76.59
Net Income
313.75
+212.79%
-278.16
+36.82%
-440.24
+61.08%
-1,131.16
Pretax Income
323.15
+185.63%
-377.38
+12.95%
-433.52
+61.53%
-1,126.99
Net Non Operating Interest Income Expense
-141.16
-610.55%
-19.87
+22.58%
-25.66
+80.44%
-131.16
Interest Expense Non Operating
252.63
+78.08%
141.86
+17.02%
121.22
-22.28%
155.97
Net Interest Income
-141.16
-610.55%
-19.87
+22.58%
-25.66
+80.44%
-131.16
Interest Expense
252.63
+78.08%
141.86
+17.02%
121.22
-22.28%
155.97
Interest Income Non Operating
111.47
-8.63%
121.99
+27.66%
95.56
+285.20%
24.81
Interest Income
111.47
-8.63%
121.99
+27.66%
95.56
+285.20%
24.81
Other Income Expense
-37.27
+79.37%
-180.62
-43.72%
-125.68
+40.37%
-210.76
Other Non Operating Income Expenses
7.51
+209.92%
-6.83
+61.49%
-17.74
-185.96%
-6.20
Gain On Sale Of Security
-2.31
+98.67%
-173.79
-61.01%
-107.94
+15.65%
-127.97
Tax Provision
9.40
+109.48%
-99.22
-1575.36%
6.72
+61.54%
4.16
Tax Rate For Calcs
0.00
-88.97%
0.00
+25.24%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-1.30
+97.16%
-45.71
-101.64%
-22.67
+47.23%
-42.96
Net Income Including Noncontrolling Interests
313.75
+212.79%
-278.16
+36.82%
-440.24
+61.08%
-1,131.16
Net Income From Continuing Operation Net Minority Interest
313.75
+212.79%
-278.16
+36.82%
-440.24
+61.08%
-1,131.16
Net Income From Continuing And Discontinued Operation
313.75
+212.79%
-278.16
+36.82%
-440.24
+61.08%
-1,131.16
Net Income Continuous Operations
313.75
+212.79%
-278.16
+36.82%
-440.24
+61.08%
-1,131.16
Normalized Income
357.23
+338.04%
-150.07
+57.72%
-354.97
+63.39%
-969.56
Net Income Common Stockholders
313.75
+212.79%
-278.16
+36.82%
-440.24
+61.08%
-1,131.16
Diluted EPS
2.33
+206.88%
-2.18
+38.07%
-3.52
+62.15%
-9.30
Basic EPS
2.39
+209.63%
-2.18
+38.07%
-3.52
+62.15%
-9.30
Basic Average Shares
131.00
+2.63%
127.65
+2.20%
124.91
+2.64%
121.69
Diluted Average Shares
134.68
+5.51%
127.65
+2.20%
124.91
+2.64%
121.69
Diluted NI Availto Com Stockholders
313.75
+212.79%
-278.16
+36.82%
-440.24
+61.08%
-1,131.16
Rent And Landing Fees
193.44
+13.85%
169.91
+16.63%
145.69
+10.40%
131.97
Rent Expense Supplemental
193.44
+13.85%
169.91
+16.63%
145.69
+10.40%
131.97
Line Item Trend 2023-12-31
Total Assets
3,829.88
Current Assets
2,982.70
Cash Cash Equivalents And Short Term Investments
2,439.38
Cash And Cash Equivalents
812.69
Other Short Term Investments
1,626.69
Receivables
327.79
Accounts Receivable
327.79
Inventory
89.15
Raw Materials
—
Work In Process
—
Finished Goods
—
Prepaid Assets
—
Other Current Assets
126.38
Total Non Current Assets
847.18
Net PPE
725.79
Gross PPE
948.87
Accumulated Depreciation
-223.08
Properties
0.00
Land And Improvements
9.08
Buildings And Improvements
271.65
Machinery Furniture Equipment
47.77
Construction In Progress
30.10
Other Properties
354.86
Leases
235.41
Non Current Deferred Assets
10.10
Non Current Deferred Taxes Assets
10.10
Other Non Current Assets
111.29
Total Liabilities Net Minority Interest
4,050.52
Current Liabilities
967.79
Payables And Accrued Expenses
646.36
Payables
55.52
Accounts Payable
55.52
Current Accrued Expenses
590.84
Pensionand Other Post Retirement Benefit Plans Current
122.17
Current Debt And Capital Lease Obligation
41.51
Current Capital Lease Obligation
41.51
Current Deferred Liabilities
102.75
Current Deferred Revenue
102.75
Other Current Liabilities
54.99
Total Non Current Liabilities Net Minority Interest
3,082.74
Long Term Debt And Capital Lease Obligation
1,263.88
Long Term Debt
1,020.78
Long Term Capital Lease Obligation
243.10
Non Current Deferred Liabilities
188.18
Non Current Deferred Revenue
188.18
Other Non Current Liabilities
1,630.69
Stockholders Equity
-220.64
Common Stock Equity
-220.64
Capital Stock
1.26
Common Stock
1.26
Preferred Stock
0.00
Share Issued
125.79
Ordinary Shares Number
125.79
Treasury Shares Number
0.00
Additional Paid In Capital
6,811.06
Retained Earnings
-7,009.59
Gains Losses Not Affecting Retained Earnings
-23.38
Other Equity Adjustments
-23.38
Total Equity Gross Minority Interest
-220.64
Total Capitalization
800.13
Working Capital
2,014.91
Invested Capital
800.13
Total Debt
1,305.39
Net Debt
208.09
Capital Lease Obligations
284.61
Net Tangible Assets
-220.64
Tangible Book Value
-220.64
Derivative Product Liabilities
—
Inventories Adjustments Allowances
—
Other Inventories
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
524.08
+6405.10%
-8.31
-107.98%
104.16
+119.24%
-541.27
Cash Flow From Continuing Operating Activities
524.08
+6405.10%
-8.31
-107.98%
104.16
+119.24%
-541.27
Net Income From Continuing Operations
313.75
+212.79%
-278.16
+36.82%
-440.24
+61.08%
-1,131.16
Depreciation Amortization Depletion
55.66
-1.79%
56.67
+4.84%
54.05
+21.56%
44.47
Depreciation
—
—
97.03
+13.42%
85.55
Depreciation And Amortization
55.66
-1.79%
56.67
+4.84%
54.05
+21.56%
44.47
Other Non Cash Items
251.11
+184.89%
88.14
-15.39%
104.17
+0.15%
104.02
Stock Based Compensation
348.24
+27.99%
272.08
+22.74%
221.68
-3.89%
230.65
Deferred Tax
-2.20
+97.94%
-106.76
-14873.63%
-0.71
+50.24%
-1.43
Deferred Income Tax
-2.20
+97.94%
-106.76
-14873.63%
-0.71
+50.24%
-1.43
Operating Gains Losses
2.31
-98.67%
173.79
+61.01%
107.94
-47.23%
204.56
Gain Loss On Investment Securities
2.31
-98.67%
173.79
+61.01%
107.94
-15.65%
127.97
Change In Working Capital
-444.78
-107.76%
-214.08
-473.87%
57.26
+651.65%
7.62
Change In Receivables
-359.96
-315.90%
-86.55
+1.58%
-87.94
-92.86%
-45.60
Changes In Account Receivables
-359.96
-315.90%
-86.55
+1.58%
-87.94
-92.86%
-45.60
Change In Inventory
8.47
-37.65%
13.59
-26.01%
18.37
+153.81%
-34.14
Change In Prepaid Assets
-117.72
-3745.83%
3.23
+135.76%
-9.03
+76.55%
-38.51
Change In Payables And Accrued Expense
75.07
-17.59%
91.09
+12.68%
80.84
-57.85%
191.77
Change In Payable
75.07
-17.59%
91.09
+12.68%
80.84
-57.85%
191.77
Change In Account Payable
75.07
-17.59%
91.09
+12.68%
80.84
-57.85%
191.77
Change In Other Working Capital
-50.63
+78.49%
-235.45
-527.91%
55.02
+183.48%
-65.91
Change In Other Current Liabilities
—
—
-46.50
-7.72%
-43.17
Investing Cash Flow
436.33
+473.44%
-116.84
+65.26%
-336.35
-298.61%
169.35
Cash Flow From Continuing Investing Activities
436.33
+473.44%
-116.84
+65.26%
-336.35
-298.61%
169.35
Net PPE Purchase And Sale
-58.70
-71.24%
-34.28
+44.90%
-62.21
+13.67%
-72.06
Purchase Of PPE
-58.70
-71.24%
-34.28
+44.90%
-62.21
+13.67%
-72.06
Capital Expenditure
-58.70
-71.24%
-34.28
+44.90%
-62.21
+13.67%
-72.06
Net Investment Purchase And Sale
497.18
+886.10%
-63.25
+76.55%
-269.70
-205.93%
254.61
Purchase Of Investment
-1,305.08
+20.17%
-1,634.91
+10.34%
-1,823.50
+7.76%
-1,976.96
Sale Of Investment
1,802.26
+14.67%
1,571.66
+1.15%
1,553.80
-30.37%
2,231.57
Net Other Investing Changes
-2.15
+88.87%
-19.32
-335.26%
-4.44
+66.36%
-13.19
Financing Cash Flow
-305.19
-203.75%
294.16
+70.89%
172.13
-59.57%
425.75
Cash Flow From Continuing Financing Activities
-305.19
-203.75%
294.16
+70.89%
172.13
-59.57%
425.75
Net Issuance Payments Of Debt
-544.53
0.00
0.00
-100.00%
254.00
Issuance Of Debt
645.69
0.00
0.00
-100.00%
1,016.11
Repayment Of Debt
-1,190.22
0.00
0.00
+100.00%
-762.11
Long Term Debt Issuance
645.69
0.00
0.00
-100.00%
1,016.11
Long Term Debt Payments
-1,190.22
0.00
0.00
+100.00%
-762.11
Net Long Term Debt Issuance
-544.53
0.00
0.00
-100.00%
254.00
Net Common Stock Issuance
—
—
—
0.00
Proceeds From Stock Option Exercised
250.03
-17.47%
302.95
+105.44%
147.46
-43.14%
259.36
Net Other Financing Charges
-10.69
-21.54%
-8.79
-135.64%
24.67
+128.16%
-87.61
Changes In Cash
655.22
+287.69%
169.01
+381.38%
-60.06
-211.57%
53.83
Effect Of Exchange Rate Changes
34.94
+329.25%
-15.24
-338.44%
6.39
+186.02%
-7.43
Beginning Cash Position
968.65
+18.87%
814.88
-6.18%
868.56
+5.64%
822.15
End Cash Position
1,658.81
+71.25%
968.65
+18.87%
814.88
-6.18%
868.56
Free Cash Flow
465.38
+1192.73%
-42.59
-201.54%
41.95
+106.84%
-613.33
Interest Paid Supplemental Data
218.71
+223.64%
67.58
+110.41%
32.12
-29.00%
45.23
Income Tax Paid Supplemental Data
—
14.36
+138.50%
6.02
+126.87%
2.65
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category